Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial

BACKGROUND: Hyperbaric oxygen (HBO(2)) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO(2) in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction. METHODS: This was a mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannellotto, Mariana, Duarte, Mariano, Keller, Guillermo, Larrea, Ramiro, Cunto, Eleonora, Chediack, Viviana, Mansur, Mariela, Brito, Daniela M, García, Elizabeth, Di Salvo, Héctor E, Verdini, Fabrizio, Domínguez, Cecilia, Jorda-Vargas, Liliana, Roberti, Javier, Di Girolamo, Guillermo, Estrada, Esteban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678559/
https://www.ncbi.nlm.nih.gov/pubmed/34907003
http://dx.doi.org/10.1136/emermed-2021-211253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678559/
https://www.ncbi.nlm.nih.gov/pubmed/34907003
http://dx.doi.org/10.1136/emermed-2021-211253

Ejemplares similares